Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesFennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
11.205 USD 0.56 ( 5.31%)
Last update at 2026-11-12T15:40:00Z
VOLUME
47834
Market Cap
225.47M

Momentum Score

…

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.26
Low
11.30
High
52 Week Price Range
5.51
Low
9.92
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Fennec Pharmaceuticals is a specialty company commercializing PEDMARK (intravenous sodium thiosulfate) to reduce cisplatin‑induced hearing loss in pediatric cancer patients. Long‑term growth may be supported by uptake in pediatric oncology, guideline inclusion and reimbursement, geographic expansion and potential label extension. The therapy targets a defined unmet supportive‑care need with an approved product that could support predictable clinical use.

Principal risks include single‑product concentration in a small pediatric market, dependence on payer reimbursement and prescribing behavior, competition from alternative strategies and execution and financing risk.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.64
Dividend Yield
-
Revenue TTM
44.64M
Revenue Per Share
1.56
Gross Profit TTM
40.88M
Debt / Equity
-3.29
ROE
-65.82%
Net Debt
-36.72M
ROCE
-11.52%
Diluted EPS TTM
-0.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -10.27M -0.07M -16.05M -23.71M -17.35M
Net income -10.27M -0.44M -16.05M -24.84M -17.46M
Selling general administrative 46.91M 23.05M 20.59M 17.72M 12.24M
Selling and marketing expenses - 18.43M 12.12M 2.79M -
Gross profit 41.59M 44.35M 19.99M 1.45M -
Reconciled depreciation 0.10M 0.80M 0.29M - 0.02M
Ebit - 4.00M -12.65M -22.59M -17.22M
Ebitda -6.86M 4.80M -12.36M -22.54M -17.18M
Depreciation and amortization - 0.80M 0.29M 0.05M 0.04M
Non operating income net other - - - - -0.12M
Operating income -6.86M 2.57M -12.77M -22.59M -17.22M
Other operating expenses 52.29M 44.97M 34.02M 24.12M 17.22M
Interest expense 2.18M 4.07M 3.39M 0.98M 0.13M
Tax provision 0.11M 0.36M 0.00M - -
Interest income 0.79M 1.68M 0.48M 0.20M 0.05M
Net interest income -1.29M -2.48M -2.89M -0.93M -0.07M
Income tax expense - 0.36M 0.00M 1.12M 0.11M
Total revenue 45.42M 47.54M 21.25M 1.53M 0.00M
Total operating expenses 48.46M 41.79M 32.76M 24.04M 17.22M
Cost of revenue 3.83M 3.18M 1.26M 0.09M -
Total other income expense net -3.41M -2.64M -3.27M -1.12M -0.12M
Net income from continuing ops -9.74M -0.44M -20.22M -23.71M -17.35M
Net income applicable to common shares - - - -23.71M -17.35M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 70.07M 44.95M 26.73M 26.94M 22.41M
Other current assets 5.10M 3.55M 2.61M 0.06M 0.25M
Total liab 35.02M 50.82M 38.29M 29.51M 6.64M
Total stockholder equity 35.05M -5.87M -11.56M -2.57M 15.77M
Deferred long term liab - - - 0.21M 0.03M
Other current liab 5.62M 3.68M 3.76M 2.22M 0.88M
Common stock 189.56M 145.61M 143.57M 142.59M 140.80M
Capital stock 189.91M 145.61M 144.31M 142.59M 140.80M
Retained earnings -229.36M -219.68M -218.12M -203.20M -179.49M
Other liab - - - 0.26M 4.99M
Other assets - - -0.00M 0.21M 0.03M
Cash 36.72M 26.63M 13.20M 23.77M 21.10M
Total current liabilities 10.50M 6.92M 7.51M 4.61M 1.65M
Current deferred revenue 0.25M 0.25M -0.02M - -
Net debt -36.72M -7.29M 16.38M 1.12M -16.11M
Short term debt - 0.00M 0.02M - -0.01M
Short long term debt total - 19.34M 29.58M 24.90M 4.99M
Other stockholder equity 73.61M 66.96M 61.76M 56.80M 53.21M
Total current assets 66.56M 44.12M 26.72M 26.73M 22.39M
Net tangible assets - - - -2.57M 15.77M
Net receivables 23.18M 12.88M 8.77M 1.54M -
Long term debt - 19.34M 30.93M 24.90M 4.99M
Inventory 1.56M 1.06M 2.14M 0.58M -
Accounts payable 4.63M 3.24M 3.76M 2.39M 0.78M
Accumulated other comprehensive income 1.24M 1.24M 1.24M 1.24M 1.24M
Common stock total equity - - - - 140.80M
Retained earnings total equity - - - - -179.49M
Non currrent assets other 3.50M 0.82M 0.01M 0.21M 0.03M
Non current assets total 3.50M 0.82M 0.01M 0.21M 0.03M
Capital lease obligations 0.00M 0.00M 0.02M - -
Long term debt total - - - - 4.99M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - 1.61M -0.79M
Net borrowings -19.48M -13.00M 5.00M 20.17M 4.99M
Total cash from financing activities 22.63M -13.62M 6.64M 20.73M 4.98M
Change to operating activities - - - 1.61M -0.14M
Net income -10.27M -0.44M -16.05M -23.71M -17.35M
Change in cash 10.15M 13.37M -10.51M 2.67M -9.24M
Begin period cash flow 26.63M 13.27M 23.77M 21.10M 30.34M
End period cash flow 36.79M 26.63M 13.27M 23.77M 21.10M
Total cash from operating activities -12.47M 26.98M -17.14M -18.06M -14.22M
Issuance of capital stock 42.05M 0.00M - - 0.00M
Depreciation 0.10M 0.96M 0.29M 0.13M 0.01M
Change to inventory -1.30M 0.58M -1.58M -0.58M -0.58M
Change to account receivables -12.66M -7.87M -7.27M -1.54M -1.54M
Sale purchase of stock - -0.18M -0.08M - -0.01M
Other cashflows from financing activities -2.57M -0.44M 1.72M 25.73M 4.98M
Change to netincome - - - 4.40M 4.04M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Cash flows other operating - - - - -0.21M
Cash and cash equivalents changes - - - - -9.24M
Change in working capital -15.09M -7.33M -8.17M 1.10M -0.93M
Stock based compensation 7.03M 5.06M 5.35M 4.09M 3.75M
Other non cash items 5.76M 28.73M 1.43M 0.33M 0.31M
Free cash flow -12.47M 26.98M -17.14M -18.06M -14.22M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FENC
Fennec Pharmaceuticals Inc		 0.56
5.31%		 11.21 - 20.92 5.05 6.36 4.28 20.27
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709

919 636 4530

https://www.fennecpharma.com

35

Name Title Year Born
Mr. Rostislav Raykov CEO & Director 1976
Mr. Robert C. Andrade Chief Financial Officer 1975
Mr. Mark Meier Sr. VP of Commercial NA
Mr. Mark Gowland Controller NA
Mr. Lei Fang Pres of Pharstat Inc NA
Ms. Anne McKay Regulatory Consultant 1954
Mr. Alexander D. Smith M.S. Consultant NA
Mr. Adrian J. Haigh Chief Operating Officer 1959
Mr. Lei Fang President of Pharstat Inc NA
Mr. Jeffrey S. Hackman CEO & Director 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…